Company intelligence / Profile preview

TauC3 Biologics Limited

London, England, United Kingdomstevenagecatalyst.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

TauC3 Biologics’ lead program, TBL‑100—a humanized monoclonal antibody targeting the highly pathogenic tauC3 fragment—has shown strong preclinical activity including high affinity/specificity for its target. The company claims demonstrated evidence of target engagement and disease-modifying potential in animal models. No published clinical results yet.

Therapeutic areas: Neurology
Modalities: monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

C2N-8E12

Phase 1

Indications: Progressive supranuclear palsy, Frontotemporal dementia, Alzheimer's disease, Corticobasal degeneration

Partnerships

LifeArc – collaboration to humanize the lead monoclonal antibody TBL‑100

Beyond the preview

Go deeper on TauC3 Biologics Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TauC3 Biologics Limited.

Explore the full profile